Literature DB >> 26321683

Clinical radiotherapy audits in Belgium, 2011-2014.

P G M Scalliet1.   

Abstract

Systematic clinical radiotherapy audits have been introduced in Belgium in 2011, as part of the Federal Cancer Plan. This is in compliance with article 11 of the 97/43 Council directive of Euratom states, translated into the Belgian legislation by royal decree in 2002. The principle of clinical audits has thus been part of the federal legal requirements for more than 10 years. However, its application had to wait for the development of a practical approach: what authority will audit, who will be the auditors, along which methodology, at what frequency, etc. Since 2002, the Federal College of Radiotherapy has the mission to monitor quality of radiotherapy at large. It was therefore decided after discussions with the relevant administration at the Ministry of Health and the Federal Agency for Nuclear Control that the College would practically organise the audits. Early in the 2000s, the IAEA developed a manual for comprehensive audits, as a tool for quality improvement. Auditors were professionals of the domain and the audit visit took the form of a peer review. Great care was taken to assemble an audit party able to cover all aspects of clinical radiotherapy with a radiation oncologist, a medical physicist, a radiation therapist and, on demand, a quality officer. The IAEA manual contains a series of questionnaires to be prepared by the audited centre in advance (pre-audit and self-assessment), indicating what specific areas the auditors would assess. It is also a template for the auditors, ensuring that no area is left aside or forgotten during the site visit. The report, at the end of the visit, is drafted according to a specific report template, also developed by IAEA. Several members of the Belgian radiotherapy community have developed their auditor's skills by participating to the IAEA audit program; they are the core of the auditor Belgian team.
Copyright © 2015 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Audit; Quality; Qualité; Rapport; Reporting

Mesh:

Year:  2015        PMID: 26321683     DOI: 10.1016/j.canrad.2015.05.006

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

1.  Improving radiation oncology through clinical audits: Introducing the IROCA project.

Authors:  Maria Glòria Torras; Magdalena Fundowicz; Luisa Aliste; Esther Asensio; Anna Maria Boladeras; Josep Maria Borràs; Luísa Carvalho; Carla Castro; Letizia Deantonio; Ewelina Konstanty; Marco Krengli; Marta Kruszyna; Joana Lencart; Miquel Macià; Susanna Marín; Carles Muñoz-Montplet; Carla Pisani; Diana Pinto; Montserrat Puigdemont; Ferran Guedea; Artur Aguiar; Piotr Milecki; Julian Malicki
Journal:  Rep Pract Oncol Radiother       Date:  2017-08-11

2.  Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres.

Authors:  Carla Lopes de Castro; Magdalena Fundowicz; Alvar Roselló; Josep Jové; Letizia Deantonio; Artur Aguiar; Carla Pisani; Salvador Villà; Anna Boladeras; Ewelina Konstanty; Marta Kruszyna-Mochalska; Piotr Milecki; Diego Jurado-Bruggeman; Joana Lencart; Ignasi Modolell; Carles Muñoz-Montplet; Luisa Aliste; Maria Gloria Torras; Montserrat Puigdemont; Luísa Carvalho; Marco Krengli; Ferran Guedea; Julian Malicki
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

Review 3.  Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project.

Authors:  Magdalena Fundowicz; Artur Aguiar; Carla Lopes de Castro; Maria Glòria Torras; Letizia Deantonio; Ewelina Konstanty; Marta Kruszyna-Mochalska; Miquel Macia; Eugeni Canals; Monica Caro; Carla Pisani; Dorota Zwierzchowska; Jaume Molero; Arantxa Eraso; Joana Lencart; Carles Muñoz-Montplet; Luisa Carvalho; Marco Krengli; Julian Malicki; Ferran Guedea
Journal:  Radiat Oncol       Date:  2020-08-27       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.